Wednesday, June 30, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

Video Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Multiple Myeloma

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Wednesday, June 30th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Natalie S Callander, MD
Professor of Medicine
Director, Myeloma Clinical Program
Interim Director, Bone Marrow Transplant Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Shaji K Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Additional faculty to be announced.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.

Newly Diagnosed Multiple Myeloma (MM)

  • Disparities in incidence, treatment and mortality of MM among various racial and ethnic groups; prognostic implications of unequal access to care among African Americans and other minorities with MM
  • Clinical, biologic and logistical factors in the selection of induction therapy for patients with newly diagnosed MM
  • Clinical and research implications of available efficacy and safety findings from the Phase III ENDURANCE trial evaluating KRd (carfilzomib, lenalidomide and dexamethasone) versus RVd (lenalidomide, bortezomib and dexamethasone) as initial therapy for newly diagnosed MM
  • Ongoing investigation and published findings from Phase III trials evaluating daratumumab-containing regimens for newly diagnosed MM; current clinical role of RVd/daratumumab for patients who are eligible or ineligible for transplant as initial therapy
  • Published research evaluating the correlation between minimal residual disease (MRD) negativity and long-term outcomes for patients with newly diagnosed MM undergoing active treatment; role of MRD assessment in routine clinical decision-making
  • Selection of MRD testing methodology; limitations and advantages of commercially available platforms
  • Optimal approach to maintenance therapy; high-risk disease features, patient response to induction therapy and other factors in treatment choice
  • Available efficacy and safety outcomes with ixazomib as maintenance therapy (eg, from the TOURMALINE-MM3, TOURMALINE-MM4 and BMT CTN 1302 trials); current indications, if any

Relapsed/Refractory (R/R) MM

  • Clinical, biologic and practical factors in the selection and sequencing of available therapies for patients with R/R MM
  • Mechanism of action of selinexor and published research leading to the FDA approval of multiregimen-refractory MM; optimal incorporation into current practice
  • Results from the Phase III BOSTON trial evaluating selinexor in combination with bortezomib and dexamethasone; clinical implications
  • Key efficacy and safety findings supporting the FDA approval of daratumumab in combination with carfilzomib and dexamethasone for patients with R/R MM (CANDOR and EQUULEUS trials)
  • Mechanism of action of isatuximab; structural and pharmacologic similarities and differences between isatuximab and daratumumab and the implications, if any, for activity and tolerability
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III ICARIA-MM and IKEMA trials; FDA-approved indication for isatuximab and current and potential clinical role
  • Mechanism of action of belantamab mafodotin and efficacy and safety results from the Phase II DREAMM-2 study evaluating that agent for R/R MM; preliminary findings from DREAMM-6 evaluating belantamab mafodotin in combination with bortezomib/dexamethasone
  • FDA approval of belantamab mafodotin and incorporation into routine practice; monitoring for and management of ocular and other toxicities
  • Compositional and mechanistic similarities and differences among BCMA-targeted chimeric antigen receptor (CAR) T-cell platforms under investigation for MM
  • Design, eligibility criteria and available efficacy and safety results from the pivotal Phase II KarMMa trial evaluating idecabtagene vicleucel for R/R MM; recent FDA approval and potential clinical role of idecabtagene vicleucel
  • Early data with and ongoing clinical research evaluating other CAR T-cell platforms (eg, ciltacabtagene autoleucel, orvacabtagene autoleucel, bb21217) for MM
  • Early activity and safety data with venetoclax-based regimens for patients with and without t(11;14) and high Bcl-2 expression
  • Current nonresearch role, if any, of venetoclax in the treatment of MM
  • Mechanism of action of melflufen; similarities and differences between melflufen and standard melphalan
  • Published efficacy and safety data with and ongoing evaluation of melflufen for refractory MM
  • Mechanism of action of iberdomide and CC-92480; similarities and differences between CELMoDs and other IMiDs and activity and safety observed in patients with heavily pretreated MM
  • Efficacy and safety of investigational bispecific antibodies (eg, elranatamab, teclistamab, talquetamab) in patients with R/R MM
  • Other novel strategies in clinical development for MM

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

Learning Objectives

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and relapsed/refractory (R/R) MM.
  • Appreciate available clinical trial data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of established regimens in the treatment of R/R MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies (eg, isatuximab, melflufen, selinexor, belantamab mafodotin) to facilitate integration of these agents into MM management algorithms.
  • Recognize published research data supporting the recent FDA approval of idecabtagene vicleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA), for R/R MM, and use this knowledge to identify patients who may be appropriate for a clinical trial of this approach.
  • Discuss available data documenting the activity of bispecific T-cell engagers, antibody-drug conjugates and other CAR T-cell therapies designed to target BCMA, and use this knowledge to identify patients with MM who may be eligible for clinical trials of these approaches.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for MM, and obtain consent from appropriate patients for study participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.